Prostate Cancer

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the Abstract June 3, 2026

Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States. June 3, 2026

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. June 3, 2026

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. June 3, 2026

Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer. June 2, 2026

Phase I design for partially ordered groups with late-onset toxicity. June 2, 2026

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study. June 2, 2026

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. June 2, 2026

Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study. June 1, 2026

ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes. June 1, 2026

Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. June 3, 2026

One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. June 3, 2026

Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study. June 3, 2026

Comparison of platinum and gold fiducial markers for prostate radiotherapy: a phantom study. June 2, 2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. June 2, 2026

Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial. June 2, 2026

Perioperative Apalutamide in High-Risk Localized Prostate Cancer. June 2, 2026

Serum micronutrient levels in men with prostate carcinoma: An observational study at a tertiary care health facility. June 1, 2026

Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk. June 1, 2026

Success and Limitations of PSMA RLT : The Nuclear Medicine View. June 1, 2026

Page 1 of 1634